Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-03-01 Sale | 2024-03-05 4:09 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 3,324 | $16.02 | $53,253 | 251,235 (Direct) | View |
2024-03-01 Sale | 2024-03-05 4:08 pm | NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology | 2,519 | $16.02 | $40,358 | 160,098 (Direct) | View |
2024-02-28 Sale | 2024-02-29 4:38 pm | NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology | 2,078 | $16.14 | $33,545 | 318,965 (Direct) | View |
2024-02-28 Sale | 2024-02-29 4:28 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 2,303 | $16.14 | $37,177 | 326,479 (Direct) | View |
2023-11-07 Sale | 2023-11-08 4:22 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer | 382 | $12.65 | $4,832 | 124,511 (Direct) | View |
2023-09-01 Sale | 2023-09-05 4:24 pm | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 883 | $21.82 | $19,265 | 99,650 (Direct) | View |
2023-09-01 Sale | 2023-09-05 4:24 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 294 | $21.82 | $6,414 | 209,825 (Direct) | View |
2023-09-01 Sale | 2023-09-05 4:23 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer | 273 | $21.82 | $5,956 | 124,893 (Direct) | View |
2023-08-02 Sale | 2023-08-04 4:02 pm | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 1,144 | $30.25 | $34,607 | 100,533 (Direct) | View |
2023-03-03 Sale | 2023-03-07 4:52 pm | NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US | 13,609 | $75.55 | $1,028,165 | 54,284 (Direct) | View |
2023-03-03 Sale | 2023-03-07 4:52 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer | 21,421 | $76.16 | $1,631,411 | 124,799 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-02-27 Option Award | 2024-02-29 4:43 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 258,597 | $16.3 | 376,215 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:38 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology | 258,597 | $16.3 | 318,965 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:36 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer | 181,017 | $16.3 | 218,610 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:35 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer | 206,877 | $16.3 | 296,226 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:33 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Leupin Nicolas Chief Medical Officer | 129,298 | $16.3 | 129,298 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:33 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer | 129,298 | $16.3 | 147,945 (Direct) | View |
2023-12-31 Option Award | 2024-02-29 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | Ben Arye Barak General Counsel | 128 | $12.69 | 242,200 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:30 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | Ben Arye Barak General Counsel | 206,877 | $16.3 | 242,200 (Direct) | View |
2023-12-31 Option Award | 2024-02-29 4:28 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 3 | $12.69 | 326,479 (Direct) | View |
2024-02-27 Option Award | 2024-02-29 4:28 pm | 2025-02-27 2034-02-26 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 118,954 | $16.3 | 326,479 (Direct) | View |
Ownership | 2024-01-12 4:57 pm | N/A N/A | NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology | 0 | $0 | 227,173 (Direct) | View |
Ownership | 2023-12-20 4:23 pm | N/A N/A | NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer | 0 | $0 | 61,032 (Direct) | View |
2023-10-31 Option Award | 2023-11-03 4:08 pm | N/A N/A | NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer | 37,593 | $0 | 95,197 (Direct) | View |
2023-10-31 Option Award | 2023-11-03 4:08 pm | 2024-10-31 2033-10-30 | NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer | 57,604 | $13.3 | 95,197 (Direct) | View |
2023-10-31 Exercise | 2023-11-02 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 7,736 | $11.46 | 117,793 (Direct) | View |
2023-10-31 Exercise | 2023-11-02 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 2,480 | $11.44 | 117,793 (Direct) | View |
2023-10-31 Exercise | 2023-11-02 4:20 pm | N/A 2026-02-24 | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 17,968 | $0 | 117,793 (Direct) | View |
2023-10-31 Exercise | 2023-11-02 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 7,752 | $7.15 | 117,793 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:15 pm | N/A N/A | NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer | 305 | $35.28 | 89,349 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:14 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 366 | $35.28 | 210,119 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:14 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer | 367 | $35.28 | 125,166 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:14 pm | N/A N/A | NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer | 357 | $35.28 | 66,447 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | Ben Arye Barak General Counsel | 288 | $35.28 | 35,195 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer | 367 | $35.28 | 101,677 (Direct) | View |
2023-06-30 Option Award | 2023-07-06 4:12 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer | 367 | $35.28 | 13,989 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:05 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | VERNON W ANTHONY Director | 10,130 | $0 | 172,074 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:05 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | Scannell Timothy J Director | 10,130 | $0 | 10,205 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:04 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | Hung David Director | 12,554 | $0 | 12,554 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:04 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | Madden Martin J. Director | 12,554 | $0 | 12,554 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:04 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 10,130 | $0 | 85,416 (Direct) | View |
2023-06-07 Option Award | 2023-06-09 4:04 pm | 2024-06-07 2033-06-06 | NovoCure Ltd | NVCR | HILLEMAN JERYL L Director | 12,554 | $0 | 12,554 (Direct) | View |
2023-05-09 Option Award(A) | 2023-05-17 4:58 pm | N/A 2033-05-08 | NovoCure Ltd | NVCR | Stafford Kristin Director | 15,873 | $0 | 15,873 (Direct) | View |
2023-05-09 Option Award | 2023-05-11 4:34 pm | N/A 2033-05-08 | NovoCure Ltd | NVCR | Stafford Kristin Director | 15,873 | $0 | 15,873 (Direct) | View |